Claudio Santos

Claudio Santos has a diverse work history within the biotech and venture capital industries. Claudio is currently the Chief Executive Officer at Gyala Therapeutics, a company focused on developing CAR-T therapies for hematological malignancies. In 2023, Claudio will also serve as an Entrepreneur in Residence at Invivo Capital. Prior to their current roles, Claudio was the CEO of Pulmobiotics SL, where they developed treatments and vaccines for respiratory diseases using a platform based on attenuated lung bacteria. Claudio also worked as a Consultant, providing advice on therapeutic projects, business strategy, and fundraising for various biotech companies and venture capital firms. Claudio has held executive positions at BiOncotech Therapeutics and AdoRx Therapeutics, where they played a key role in immune oncology research and strategic planning. Earlier in their career, Claudio worked as an Investment Associate at Sixth Element Capital LLP, managing venture capital investments in oncology. Claudio also served as a Business Development Manager at Cancer Research Technology and held research fellow positions at the Cancer Research UK London Research Institute. Claudio's expertise extends to event management as well, as they served as the Events Lead for Oxbridge Biotech Roundtable.

Claudio Santos completed their Bachelor of Science degree in Biology at the Universidade de Coimbra from 1996 to 2001. Following this, they pursued a Doctor of Philosophy (PhD) in Biological and Clinical Cancer at the Universidad de Salamanca from 2002 to 2006.